Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18‑month observational study of JC virus immune response in MS patients treated with fingolimod
jRCT1080224761Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fingolimod in multiple sclerosis (MS) (2 cohorts), sponsored by Novartis. Primary endpoint: Immune response against JC virus. Started Jul 2019; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT1080224761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224761.